Evithé biotechnology is expanding the global medicines toolbox by harnessing millions of years of plant evolution into novel botanical drugs with the intention to cure, mitigate, treat or prevent disease in humans.
Our surveys identified a significant market pull with 78% of consumers indicating to prefer a botanical drug over a synthetic chemical, and 70% of practitioners are confident in prescribing botanical drugs.
Evithé biotechnology is inspired by the way that plants have evolved over thousands of years and has found a way to harness their actions into novel botanical drugs with the intention to cure, mitigate, treat or prevent disease in humans.
The Botanical Drug Development Project won multiple awards including:
Our botanical drug development process is set out to support people with auto-inflammatory diseases. Auto-inflammation is a disease process where the bodies immune system tries to fight an infection, panics and accidentally self-destructs, causing tissue and organ damage.
Auto-inflammation affects 4% of the world population in a variety of degrees of severity from sepsis, to diseases like rheumatoid arthritis to bladder pain, which is known as interstitial cystitis.
The drugs currently used to tackle auto-inflammation are not very effective, and typically tackling just one step in the body’s reaction.
Plants have evolved to produce an array of active constituents to treat diseases by addressing multiple targets at the same time.
Founder & CEO
Mrs Hunefeld dedicated her life, work and studies in ethnobotany, plant medicine, Post graduate Diploma in clinical research and Masters in Innovation & Commercialisation to the development of botanical medicines.
Dr Kelly brings his extensive experience in all aspects of the Innovation & Commercialisation through his long and successful career in Australia & New Zealand and his firm BioPacific Partners.
Honorary Senior Lecturer in Pharmacy at Auckland University with a deep understanding of botanical medicine and product development. Phil founded Phyomed & KiwiHerb and developed them into successful companies that distribute quality controlled botanical medicines all over the world.
Registered Trans-Tasman patent attorney with a PhD in Organic Chemistry. Jane has unique knowledge of both biotechnology and botanical drug development as well as the requirements for innovation and commercialisation pathways. She brings a wealth of practical experience in building a companies intellectual property portfolio from start-up to large corporate from laboratory to public listing.
A Master of Business Administration from New Zealand’s leading business school at the University of Auckland, Lorraine has a particular focus on innovation and strategic growth. She is an ArcAngel investor and an experienced company director on five boards, including the Gillies McIndoe Research Institute. She is a former award-winning journalist, editor, publisher and author. Titles she has edited include New Zealand Pharmacy journal and also sub-editor of The National Business Review.
Mike is an experienced angel investor and financial professional. He has directorships and investments in the funds management, glazing, indoor plant hire, social media monitoring and industrial safety sectors, and is an Angel HQ board member. He is a board adviser to Evithe and is assisting in the accounting and financial tasks and strategy.
Charlotte has recently completed a PhD in Chemistry and has a background in drug discovery and development. Charlotte assists with day-to-day operations, contributing her practical knowledge and experience to the role.”
You can also connect with Evithé through our digital channels in order to stay up to date.